A Study Evaluating the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486

NCT03745625 | Completed Phase 1

• 1 other identifier: HSK3486-102
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase I, single-center, open-label, randomized,two-way crossover, propofol-controlled, two-stage study evaluating the safety and pharmacokinetics/pharmacodynamics of IV maintenance dose after an initial dose and IV single loade dose plus maintenance dose of HSK3486 emulsion for injection in healthy subjects.

Conditions

Anesthesia; Sedation

Outcome Measures

Primary Outcomes (5)

• blood pressure（systolic, diastolic and mean arterial pressure）

  safety endpoits

  from the screening to 3 days post-dose

• heart rate

  safety endpoits

  from the screening to 3 days post-dose

• respiratory rate

  safety endpoits

  from the screening to 3 days post-dose

• blood oxygen saturation

  safety endpoits

  from the screening to 3 days post-dose

• Number of patients with adverse events

  safety endpoits

  from the baseline to 3 days post-dose

Secondary Outcomes (7)

• Richmond Agitation Sedation Scale( scores：+4~-5)

  -30 minutes before administration until the subject is completely awakened post administration on day 1

• Bispectral index

  -30 minutes before administration until the subject is completely awakened post administration on day 1

• Sedation/anesthesia satisfaction, satisfaction assessment of subjects, anesthesiologists, and endoscopic physicians

  -30 minutes before administration until the subject is completely awakened post administration on day 1

• Terminal elimination half life

  -30 minutes before administration until 24 hours post administration on day 1

• Total clearance

  -30 minutes before administration until 24 hours post administration on day 1

Other Outcomes (4)

• area under curve from time 0 to the last measurable blood sampling time (AUC0-last)

  -30 minutes before administration until 24 hours post administration on day 1

• area under curve from time 0 to infinite time (AUC0-inf)

  -30 minutes before administration until 24 hours post administration on day 1

• Peak concentration

  -30 minutes before administration until 24 hours post administration on day 1

Study Arms (2)

HSK3486

EXPERIMENTAL

First-stage: 1mg/kg/h, 0.4mg/kg/h; Second-stage:Single loading dose: 0.2mg/kg, maintenance dose: 0.35mg/kg/h,

Drug: HSK3486

Propofol

ACTIVE COMPARATOR

First-stage: 5mg/kg/h, 2mg/kg/h; Second-stage:Single load ing dose: 1mg/kg, maintenance dose: 1.75mg/kg/h

Drug: Propofol

Interventions

HSK3486 DRUG

First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h. Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h.

HSK3486

Propofol DRUG

First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h. Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h.

Propofol

Eligibility Criteria

• Age: 18 Years - 49 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy males or females with full capacity for civil conduct, aged ≥ 18 and ≤ 49 years old;
• Body weight \> 45 kg, and body mass index (BMI) ≥ 19 and ≤26 kg/m2;
• Blood pressure between 90-140/60-90 mmHg; heart rate between 60-99 bpm; body temperature between 35.8-37.5 °C; respiration rate between 12-20 breaths per minute; SpO2 when inhaling \> 95%;
• Normal physical examinations, laboratory examinations (routine blood test, blood biochemistry and routine urinalysis), and 12-Lead ECG, or abnormal but without clinical significance; no potential difficult airway (modified Mallampati score I-III);
• No previous history of major organ primary diseases, such as liver, kidneys, digestive tract, blood, and metabolic diseases; no history of malignant hyperthermia and other genetic conditions; no history of mental/neurological diseases; No history of epilepsy; no contraindications for deep sedation/general anesthesia; no clinically significant history of anesthesia accidents;
• Subjects must understand the procedures and methods of this study, and be willing to provide informed consent and to complete the trial in strict accordance with trial protocol.

You may not qualify if:

• Known sensitivity to propofol, excipients in propofol medium-/long-chain triglyceride emulsion injection, excipients in HSK3486 emulsion injection (soybean oil, glycerin, triglyceride, egg lecithin, sodium oleate, and sodium hydroxide); history of drug allergies (including anesthetics), allergic diseases, or those with hyperactive immune response;
• History of drug abuse or any signs of chronic benzodiazepines use (such as insomnia, anxiety, spasms) within 3 months prior to screening, or a positive urine drug test during screening;
• Participated in clinical trials involving any medications or medical devices within 3 months prior to screening, or subjects who have participated in 3 or more drug clinical trials within the past year;
• Serious infection, trauma or major surgery within 4 weeks before screening; or acute disease with clinical significance (determined by the investigator) within 2 weeks before screening, including GI diseases or infections (such as respiratory or CNS infections);
• In receipt of propofol, other sedatives/anesthetics and/or opioid analgesics or compounds containing analgesics within 3 days prior to screening;
• In receipt of prescription drugs, Chinese herbal medicines, over-the-counter drugs or food supplements (such as vitamins and calcium supplements) other than contraceptives, paracetamol, oral non-steroidal anti-inflammatory drugs, topical over-the-counter preparations, within 2 weeks prior to enrollment; unless the principal investigator (PI) and the sponsor agree that the medication has no effect on the safety and PK/PD results of the trial;
• History of cardiovascular diseases such as: postural hypotension, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6 months before screening, tachycardia/bradycardia requiring medication, third-degree atrioventricular block or QTcF interval ≥ 450 ms (Fridericia's correction formula);
• Impaired respiratory function, history of obstructive pulmonary disease, history of asthma, sleep apnea syndromes; history of failed tracheal intubation; history of bronchospasm requiring treatment within 3 months prior to screening; acute upper respiratory tract infection, and with obvious symptoms such as fever, wheezing, nasal congestion and cough within 1 week prior to baseline;
• History of GI tract diseases: Gastrointestinal obstruction, active GI bleed, potential for reflux and aspiration;
• Laboratory results that meet any of the following during screening/enrollment:
• Positive test for either HBsAg, HCV, HIV, or syphilis;
• Abnormal hepatic or renal function confirmed after re-examination;
• ALT or AST \> 1×ULN;
• Creatinine \> 1×ULN;
• TBIL \> 1.5×ULN;

Sponsors & Collaborators

• Sichuan Haisco Pharmaceutical Group Co., Ltd: lead

Study Sites (1)

West China Hospital，Sichuan University

Chengdu, China

Location

MeSH Terms

Interventions

HSK3486; Propofol

Intervention Hierarchy (Ancestors)

Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 9, 2018
• First Posted: November 19, 2018
• Study Start: January 9, 2019
• Primary Completion: July 2, 2019
• Study Completion: August 27, 2019
• Last Updated: January 9, 2020

Record last verified: 2018-11

Locations

CN (1)